Further analysis of monocytes subpopulations with respect to CD14 and CD16 co-expression patterns revealed that PAD patients under replacement treatment exhibited higher percentages and absolute numbers of intermediate (CD14++/CD16+) and non-classical (CD14+/CD16+) monocytes compared to healthy controls. This evidence concerns the gene FCGR3B and peripheral arterial disease.